Type 2 Diabetes Treatment
Jun 18, 2024
Takeda Showcase Phase III Results for Soticlestat; Imfinzi and Chemotherapy Combination Gains US Approval; Nipocalimab Shows Notable Efficacy in Phase II Study; Bristol Myers Squibb’s Augtyro FDA Approval; AstraZeneca’s Farxiga FDA Approval
Takeda Reveals Phase III Results for Soticlestat (TAK-935) in Dravet and Lennox-Gastaut Syndromes Takeda revealed topline results from its SKYLINE and SKYWAY studies. SKYLINE (TAK-935-3001) was a multicenter, randomized, double-blind Phase III trial assessing soticlestat (TAK-935) plus standard care against plac...
Read More...
Nov 16, 2022
Insights Into the Key Advancements Transforming the Type 2 Diabetes Treatment and Management
Diabetes is a chronic metabolic disorder that is influenced by a wide variety of factors and is characterized by high or low blood glucose (or blood sugar) levels in the body. Diabetes is a major risk factor for blindness, kidney failure, heart attacks, stroke, and lower limb amputation. Also, it can significantly ...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
